Literature DB >> 18588489

Why are we afraid of Acinetobacter baumannii?

Federico Perez, Andrea Endimiani, Robert A Bonomo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18588489      PMCID： PMC4085750          DOI： 10.1586/14787210.6.3.269

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


× No keyword cloud information.
  20 in total

1.  Sampling the antibiotic resistome.

Authors:  Vanessa M D'Costa; Katherine M McGrann; Donald W Hughes; Gerard D Wright
Journal:  Science       Date:  2006-01-20       Impact factor: 47.728

Review 2.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

3.  An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq.

Authors:  Paul Scott; Gregory Deye; Arjun Srinivasan; Clinton Murray; Kimberly Moran; Ed Hulten; Joel Fishbain; David Craft; Scott Riddell; Luther Lindler; James Mancuso; Eric Milstrey; Christian T Bautista; Jean Patel; Alessa Ewell; Tacita Hamilton; Charla Gaddy; Martin Tenney; George Christopher; Kyle Petersen; Timothy Endy; Bruno Petruccelli
Journal:  Clin Infect Dis       Date:  2007-05-08       Impact factor: 9.079

4.  The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii Pneumonia.

Authors:  Rosemarijn Renckens; Joris J T H Roelofs; Sylvia Knapp; Alex F de Vos; Sandrine Florquin; Tom van der Poll
Journal:  J Infect Dis       Date:  2005-12-07       Impact factor: 5.226

5.  Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia.

Authors:  Sylvia Knapp; Catharina W Wieland; Sandrine Florquin; Ralph Pantophlet; Lenie Dijkshoorn; Ntambua Tshimbalanga; Shizuo Akira; Tom van der Poll
Journal:  Am J Respir Crit Care Med       Date:  2005-10-06       Impact factor: 21.405

Review 6.  Acinetobacter outbreaks, 1977-2000.

Authors:  Maria Virginia Villegas; Alan I Hartstein
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

Review 7.  Acinetobacter baumannii: an emerging multidrug-resistant threat.

Authors:  Thomas D Gootz; Andrea Marra
Journal:  Expert Rev Anti Infect Ther       Date:  2008-06       Impact factor: 5.091

8.  New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis.

Authors:  Michael G Smith; Tara A Gianoulis; Stefan Pukatzki; John J Mekalanos; L Nicholas Ornston; Mark Gerstein; Michael Snyder
Journal:  Genes Dev       Date:  2007-03-01       Impact factor: 11.361

9.  Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling.

Authors:  Clett Erridge; Olga L Moncayo-Nieto; Robert Morgan; Michelle Young; Ian R Poxton
Journal:  J Med Microbiol       Date:  2007-02       Impact factor: 2.472

10.  Comparative genomics of multidrug resistance in Acinetobacter baumannii.

Authors:  Pierre-Edouard Fournier; David Vallenet; Valérie Barbe; Stéphane Audic; Hiroyuki Ogata; Laurent Poirel; Hervé Richet; Catherine Robert; Sophie Mangenot; Chantal Abergel; Patrice Nordmann; Jean Weissenbach; Didier Raoult; Jean-Michel Claverie
Journal:  PLoS Genet       Date:  2006-01-13       Impact factor: 5.917
View more
  25 in total

1.  ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.

Authors:  Pablo Ravasi; Adriana S Limansky; Ramiro E Rodriguez; Alejandro M Viale; María A Mussi
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options.

Authors:  Gopi Patel; Meenakshi M Rana; Shirish Huprikar
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

3.  Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.

Authors:  R Parra Millán; M E Jiménez Mejías; V Sánchez Encinales; R Ayerbe Algaba; A Gutiérrez Valencia; M E Pachón Ibáñez; C Díaz; J Pérez Del Palacio; L F López Cortés; J Pachón; Y Smani
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Photodynamic therapy for Acinetobacter baumannii burn infections in mice.

Authors:  Tianhong Dai; George P Tegos; Zongshun Lu; Liyi Huang; Timur Zhiyentayev; Michael J Franklin; David G Baer; Michael R Hamblin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

5.  Structure-Based Analysis of Boronic Acids as Inhibitors of Acinetobacter-Derived Cephalosporinase-7, a Unique Class C β-Lactamase.

Authors:  Alexandra A Bouza; Hollister C Swanson; Kali A Smolen; Alison L VanDine; Magdalena A Taracila; Chiara Romagnoli; Emilia Caselli; Fabio Prati; Robert A Bonomo; Rachel A Powers; Bradley J Wallar
Journal:  ACS Infect Dis       Date:  2017-12-08       Impact factor: 5.084

6.  Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III.

Authors:  Scott R Evans; Andrea M Hujer; Hongyu Jiang; Carol B Hill; Kristine M Hujer; Jose R Mediavilla; Claudia Manca; Thuy Tien T Tran; T Nicholas Domitrovic; Paul G Higgins; Harald Seifert; Barry N Kreiswirth; Robin Patel; Michael R Jacobs; Liang Chen; Rangarajan Sampath; Thomas Hall; Christine Marzan; Vance G Fowler; Henry F Chambers; Robert A Bonomo
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

7.  The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Ulrike MacDonald; Andrew D Cox; Frank St Michael; Evgeny V Vinogradov; Brad Spellberg; Nicole R Luke-Marshall; Anthony A Campagnari
Journal:  Infect Immun       Date:  2013-01-07       Impact factor: 3.441

Review 8.  Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease.

Authors:  Dubert M Guerrero; Federico Perez; Nicholas G Conger; Joseph S Solomkin; Mark D Adams; Philip N Rather; Robert A Bonomo
Journal:  Surg Infect (Larchmt)       Date:  2010-02       Impact factor: 2.150

9.  Complexity of Complement Resistance Factors Expressed by Acinetobacter baumannii Needed for Survival in Human Serum.

Authors:  Amaro F Sanchez-Larrayoz; Noha M Elhosseiny; Marc G Chevrette; Yang Fu; Peter Giunta; Raúl G Spallanzani; Keerthikka Ravi; Gerald B Pier; Stephen Lory; Tomás Maira-Litrán
Journal:  J Immunol       Date:  2017-08-30       Impact factor: 5.422

10.  Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.

Authors:  Sarah M Drawz; Maja Babic; Christopher R Bethel; Magda Taracila; Anne M Distler; Claudia Ori; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.